The fight against cancer : is harnessing the immune system the ultimate strategy?
Malignancy is a micro-evolutionary phenomenon shaped by selection pressures. Chief among these is the adaptive immune system, which recognizes malignant cells as a threat and attempts to eradicate them. The task is not easily achieved - if it were, cancer would not be a part of our human experience. The field of immunotherapy has rapidly expanded over the last two decades. It has produced some of the most exciting results of 21st century medicine, and has deepened clinicians' understanding of the relationship between malignancy and the immune response. This review discusses this relationship and analyses key tools in the immunotherapy arsenal.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
British journal of hospital medicine (London, England : 2005) - 80(2019), 10 vom: 02. Okt., Seite 568-573 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Watson, Edmund [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 09.03.2020 Date Revised 09.03.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.12968/hmed.2019.80.10.568 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301966214 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301966214 | ||
| 003 | DE-627 | ||
| 005 | 20231225105723.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12968/hmed.2019.80.10.568 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1006.xml |
| 035 | |a (DE-627)NLM301966214 | ||
| 035 | |a (NLM)31589501 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Watson, Edmund |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The fight against cancer |b is harnessing the immune system the ultimate strategy? |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2020 | ||
| 500 | |a Date Revised 09.03.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Malignancy is a micro-evolutionary phenomenon shaped by selection pressures. Chief among these is the adaptive immune system, which recognizes malignant cells as a threat and attempts to eradicate them. The task is not easily achieved - if it were, cancer would not be a part of our human experience. The field of immunotherapy has rapidly expanded over the last two decades. It has produced some of the most exciting results of 21st century medicine, and has deepened clinicians' understanding of the relationship between malignancy and the immune response. This review discusses this relationship and analyses key tools in the immunotherapy arsenal | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Cancer Vaccines |2 NLM | |
| 700 | 1 | |a Danby, Robert |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of hospital medicine (London, England : 2005) |d 2005 |g 80(2019), 10 vom: 02. Okt., Seite 568-573 |w (DE-627)NLM157166031 |x 1750-8460 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2019 |g number:10 |g day:02 |g month:10 |g pages:568-573 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12968/hmed.2019.80.10.568 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2019 |e 10 |b 02 |c 10 |h 568-573 | ||